Xenetic Biosciences is a biopharmaceutical company. Co.'s drug candidates pipeline include: XCART, which is a CAR T cell platform technology engineered to target patient-specific tumor neoantigens; ErepoXen (polysialylated erythropoietin), which uses Co.'s PolyXen platform technology for the treatment of anemia in chronic kidney disease patients; XBIO-101, which is an internal candidate with orphan drug designation from the U.S. Food and Drug Administration for the potential treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy; and OncoHist, which utilizes the properties of modified human histone H1.3 for targeted cell killing. We show 39 historical shares outstanding datapoints in our XBIO shares outstanding history coverage, used to compute XBIO market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing XBIO market cap history over the course of time is important for investors
interested in comparing XBIO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of XBIO versus a peer is one thing; comparing
XBIO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like XBIO can fluctuate over the course of history.
With this page we aim to empower investors researching XBIO by allowing them to research the XBIO market cap history. |
Free XBIO Email Alerts:
Video: The Importance of Market Cap
